SEC Form 4 · accession 0001203311-16-000163

SEATTLE GENETICS INC /WA · SGEN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President and CEO · Director

Period of report

Oct 6, 2016

Accepted (ET)

Oct 11, 2016 · 4:50 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001060736

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Oct 6, 2016	M	3,242	$10.20	A	642,077	D
Common Stock^F3,F1	Oct 6, 2016	S	3,242	$54.4087	D	638,835	D
Common Stock^F1	Oct 6, 2016	M	11,223	$10.29	A	650,058	D
Common Stock^F3,F1	Oct 6, 2016	S	11,223	$54.4087	D	638,835	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-Qualified Stock Option (right to buy)^F4	$10.20	Oct 6, 2016	M	3,242	D	—	May 25, 2017	Common Stock	3,242	28,291	D
Non-Qualified Stock Option (right to buy)^F5	$10.29	Oct 6, 2016	M	11,223	D	—	Aug 28, 2017	Common Stock	11,223	104,220	D

F1Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F3Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $54.03 to $54.69. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F4Shares vested at a rate of 25% on 5/25/08 and monthly thereafter until all the shares were fully vested on 5/25/11.
F5Shares vested at a rate of 25% on 8/28/08 and monthly thereafter until all the shares were fully vested on 8/28/11.